By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.
Cookie Disclaimer
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the app and the website, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide in the Cookie Settings which categories you would like to permit. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Statement.
Cookie Disclaimer
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., setting the language).
These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.
{"analytics":"targeting","share":"targeting"}
Disclaimer
Publication of Merck KGaA, Darmstadt, Germany.
In the United States and Canada the subsidiaries of
Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.
Our goal is to develop and deliver transformative specialty medicines to patients with high unmet needs in underserved populations. We’re focused on how we can make a real difference for these patients, broadening the number of treatment options available and improving access.
In 2024, we reached around 65 million patients with our healthcare portfolio in low- and middle-income countries (LMICs). We will not stop there: our goal is to create an even bigger impact by enabling access to our medicines to 80 million patients a year by 2030.
Why we’re so passionate about improving access
At least half of the world’s population lack access to essential health services and 100 million people are pushed to poverty due to health expenses.
Underserved populations in LMICs face an uphill battle as their health systems are still evolving. At Merck KGaA, Darmstadt, Germany we are committed to addressing unmet global health needs by leveraging our core competencies, expertise, and experience throughout the global health community.
Together with our partners we’re focusing on creating meaningful patient impact. While this takes time, we remain focused on the cause.
“Two billion people worldwide still lack access to effective and affordable healthcare solutions. At Merck KGaA, Darmstadt, Germany, we set a clear focus on improving the lives of patients in low- and middle-income countries. To make sure that they get the best treatment possible, we remain committed to not only developing new medicines, but also creating sustainable access mechanisms for patients and society.”
Peter Guenter, Member of the Executive Board | CEO Healthcare
Our strategy: deeper, wider, faster
We’re committed to helping 80 million patients in LMICs by 2030 by going deeper, wider and faster to enable access in LMICs:
Going deeper through equitable pricing and health system strengthening, allowing us to use a holistic approach to reach more patient segments and treat over 80 million patients a year in LMICs by 2030.
Going wider with our innovative portfolio by increasing availability of our existing innovative products in LMICs through registration in more countries, particularly high burden LMICs.
Going faster with our future launches, shortening the gap between the first global & LMIC launches of innovative products to within 12 months after the global launch.
Our strategy is integrated across the health value chain. There is a growing consensus in the global health community and within the pharmaceutical industry that sustainable access requires an integrated approach across the health value chain to deliver complete solutions unhindered by bottlenecks.
“I believe that everyone – no matter where they live – should have access to the best healthcare possible. Our commitment to patients drive us to go deeper, wider, and faster for access in low- and middle-income countries.”
Hong Chow Head of China & International Healthcare
Examples of Our commitment to improving access
Early detection of cancer
Discover how our partnership helped reach 4.6 million people to improve awareness about the importance of early detection.
